Consequently, it is reasonable to believe that NFκB signaling pathway simultaneously functions in myocardial fibrosis and immune response in ARVC, which may be the potential intervention target. The gene discussed is NFKB1; the disease is Arrhythmogenic right ventricular dysplasia.